Savara, Inc.(SVRA)

Description: Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

---

Keywords: Medicine Pharmaceutical Clinical Development Heart Failure Respiratory Diseases Heart Disease Stage Pharmaceutical Cystic Fibrosis Staphylococcus Aureus Methicillin Treatment Of Heart Failure Vancomycin Lung Infection Autoimmune Pulmonary Alveolar Proteinosis Diastolic Heart Failure Pulmonary Alveolar Proteinosis Rare Respiratory Diseases

---

Home Page: www.savarapharma.com

SVRA Technical Analysis

Building III
Austin, TX 78746
United States
Phone: 512 614 1848

---

Officers

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)